[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580289":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":127,"collaborators":31,"id":129,"slug":130,"hasResults":131,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":31,"eligibilityCriteria":135,"healthyVolunteers":131,"sex":136,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":31,"studyType":142,"phases":143,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":45,"whyStopped":31,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":170},{"fullName":5,"class":6},"AVVA Pharmaceuticals Ltd.","INDUSTRY",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Clotrimazole+Lactulose","EXPERIMENTAL","Vaginal suppositories containing clotrimazole (100 mg) and lactulose (300 mg)",[13],"Drug: Clotrimazole+Lactulose.",{"label":15,"type":16,"description":17,"interventionNames":18},"Canesten (Clotrimazole)","ACTIVE_COMPARATOR","Vaginal tablets containing clotrimazole (100 mg)",[19],"Drug: Canesten (Clotrimazole)",{"label":21,"type":22,"description":23,"interventionNames":24},"Lactulose","PLACEBO_COMPARATOR","Vaginal suppositories containing lactulose (300 mg)",[25],"Drug: Lactulose",[27,32,34],{"type":28,"name":29,"description":11,"armGroupLabels":30,"otherNames":31},"DRUG","Clotrimazole+Lactulose.",[9],null,{"type":28,"name":15,"description":17,"armGroupLabels":33,"otherNames":31},[15],{"type":28,"name":21,"description":23,"armGroupLabels":35,"otherNames":31},[21],[37],{"name":38,"role":39,"phone":40,"phoneExt":31,"email":41},"Sergey Tolmachev","CONTACT","+7 495 2690016","tolmachev@rnd.avvapharma.com",[43,61,71,81,91,101,111],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Healthcare Institution \"1st Central District Polyclinic of the Central District of Minsk\"","RECRUITING","Minsk","Minsk City","220004","Belarus","BY",{"type":52,"coordinates":53},"Point",[54,55],27.56653,53.90019,{"lat":55,"lon":54},[58],{"name":59,"role":39,"phone":31,"phoneExt":31,"email":60},"Alina V Krakasevich","info@1crp.by",{"facility":62,"status":45,"city":46,"state":31,"zip":31,"country":49,"countryCode":50,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},"Healthcare Institution \"14th Central District Polyclinic of the Partizansky District of Minsk\"",{"type":52,"coordinates":64},[54,55],{"lat":55,"lon":54},[67],{"name":68,"role":39,"phone":69,"phoneExt":31,"email":70},"Elena V Golovko","+375 17 200 18 96","info@14crp.by",{"facility":72,"status":45,"city":46,"state":31,"zip":31,"country":49,"countryCode":50,"cosmosGeoPoint":73,"geoPoint":75,"contacts":76},"Healthcare Institution \"2nd Central District Polyclinic of the Frunzensky District of Minsk\"",{"type":52,"coordinates":74},[54,55],{"lat":55,"lon":54},[77],{"name":78,"role":39,"phone":79,"phoneExt":31,"email":80},"Elena E Yarosh","+375 17 256 56 42","lpu2crp@gmail.com",{"facility":82,"status":45,"city":46,"state":31,"zip":31,"country":49,"countryCode":50,"cosmosGeoPoint":83,"geoPoint":85,"contacts":86},"Healthcare Institution \"4th City Polyclinic\" of Minsk",{"type":52,"coordinates":84},[54,55],{"lat":55,"lon":54},[87],{"name":88,"role":39,"phone":89,"phoneExt":31,"email":90},"Elena A Malyavskaya","+375 17 374-67-69","info@4gp.by",{"facility":92,"status":45,"city":46,"state":31,"zip":31,"country":49,"countryCode":50,"cosmosGeoPoint":93,"geoPoint":95,"contacts":96},"Healthcare Institution \"5th City Clinical Polyclinic\" of Minsk",{"type":52,"coordinates":94},[54,55],{"lat":55,"lon":54},[97],{"name":98,"role":39,"phone":99,"phoneExt":31,"email":100},"Veronika D Babkova","+375 17 278 10 70","info@5gp.by",{"facility":102,"status":45,"city":46,"state":31,"zip":31,"country":49,"countryCode":50,"cosmosGeoPoint":103,"geoPoint":105,"contacts":106},"State Institution \"Republican Center of Medical Rehabilitation and Balneotherapy\"",{"type":52,"coordinates":104},[54,55],{"lat":55,"lon":54},[107],{"name":108,"role":39,"phone":109,"phoneExt":31,"email":110},"Larisa I Ershova","+375 17 358 90 92","center@makaenka17med.by",{"facility":112,"status":45,"city":113,"state":114,"zip":31,"country":115,"countryCode":116,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"SBI RR \"Regional Clinical Skin and Venereal Dispensary\"","Ryazan","Ryazan Oblast","Russia","RU",{"type":52,"coordinates":118},[119,120],39.70415,54.62696,{"lat":120,"lon":119},[123],{"name":124,"role":39,"phone":125,"phoneExt":31,"email":126},"Dmitry Sonin","+7 (4912) 27-50-82","okkvd@ryazan.gov.ru",{"type":128,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100580289","phase-2-efficacy-and-safety-of-clotrimazolelactulose-vaginal-suppositories-vs-clotrimazole-monotherapy-in-adult-women-with-candidal-vaginitisvulvovaginitis-100580289",false,"NCT06835361","Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis\u002FVulvovaginitis","International Open-label Randomized Comparative Clinical Study of Efficacy and Safety of Clotrimazole+Lactulose, Vaginal Suppositories (AVVA RUS JSC, Russia) Vs. a Clotrimazole Monocomponent Product in Adult Female Patients with Candidal Vaginitis\u002Fvulvovaginitis","Inclusion Criteria:\n\n* Women aged 18 to 60 years.\n* Clinically and microbiologically confirmed diagnosis of candidal vulvovaginitis.\n* Negative pregnancy test at screening.\n* Agreement to use reliable contraception throughout the study and for 30 days after its completion.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Diagnosed bacterial vaginosis.\n* Chronic inflammatory or atrophic diseases of the female genital organs.\n* History of malignant neoplasms.\n* Use of systemic antibiotics or antifungal drugs within 2 weeks prior to screening.","FEMALE","18 Years","60 Years",{"count":140,"type":141},264,"ESTIMATED","INTERVENTIONAL",[144,145],"PHASE2","PHASE3","This study aims to compare the efficacy and safety of the combination drug Clotrimazole+Lactulose with the monocomponent product Canesten® (clotrimazole) in adult women diagnosed with candidal vulvovaginitis. The primary objective was to confirm the superiority of the combination drug in terms of clinical and microbiological response on Day 25 of the study.",[148,149],"Candidal Vulvovaginitis (ICD-10 Code: B37.3)","Vulvovaginal Candidiasis (VVC)",[9,151,152,153,21,154,155,156,157,158,159,160],"Candidal Vulvovaginitis","Vulvovaginal Candidiasis","Clotrimazole","Antifungal Therapy","Prebiotic","Vaginal Suppositories","Canesten","Microbiological Recovery","Women's Health","Vaginal Microbiota","2025-02-14",{"date":163,"type":164},"2025-02-19","ACTUAL",{"date":166,"type":164},"2024-02-29",{"date":168,"type":141},"2025-11-30",{"name":5,"class":6},7]